{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:13:46Z","timestamp":1782742426278,"version":"3.54.5"},"reference-count":58,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis B core-related antigen (HBcrAg) is a composite measure of the serum levels of hepatitis B e antigen, hepatitis B core antigen, and a 22-kDa precore protein. It has been shown to reflect the level and transcriptional activity of covalently closed circular DNA in the liver. Longitudinal cohort studies have improved our understanding of the role of this novel viral marker in the natural history of chronic hepatitis B. HBcrAg kinetics reflect the response to peginterferon, and its role in defining guidelines for stopping peginterferon therapy has been evaluated. HBcrAg is a marker of intrahepatic viral activity, which may influence the risk of hepatocellular carcinoma. In this article, we review the virology and role of HBcrAg in defining phases of chronic hepatitis B. Furthermore, the function of HBcrAg in predicting treatment outcomes and its role in monitoring response to novel antiviral agents will be discussed.<\/jats:p>","DOI":"10.1055\/s-0041-1723088","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T22:54:59Z","timestamp":1620341699000},"page":"182-190","source":"Crossref","is-referenced-by-count":7,"title":["Hepatitis B Core-Related Antigen: From Virology to Clinical Application"],"prefix":"10.1055","volume":"41","author":[{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Yonsei Liver Center, Severance Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Yonsei Liver Center, Severance Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong"},{"name":"Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"T Tu","year":"2017","journal-title":"Viruses"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1440-1746.2010.06514.x","article-title":"JGH Foundation emerging leadership lecture. Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia","volume":"26","author":"H L Chan","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"23","key":"ref3","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.M501564200","article-title":"Hepatitis B virus DNA-negative Dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain","volume":"280","author":"T Kimura","year":"2005","journal-title":"J Biol Chem"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load","volume":"40","author":"T Kimura","year":"2002","journal-title":"J Clin Microbiol"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"L Y Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"E357","DOI":"10.3390\/genes10050357","article-title":"The role of hepatitis B core-related antigen","volume":"10","author":"T Inoue","year":"2019","journal-title":"Genes (Basel)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2019.03.003","article-title":"Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients","volume":"114","author":"G J van Halewijn","year":"2019","journal-title":"J Clin Virol"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"D K Wong","year":"2017","journal-title":"Liver Int"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","author":"E Q Chen","year":"2019","journal-title":"J Viral Hepat"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"B Testoni","year":"2019","journal-title":"J Hepatol"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/infdis\/jiv572","article-title":"Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma","volume":"213","author":"M Honda","year":"2016","journal-title":"J Infect Dis"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00535-020-01665-z","article-title":"Unresolved issues of immune tolerance in chronic hepatitis B","volume":"55","author":"H W Lee","year":"2020","journal-title":"J Gastroenterol"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu","year":"2017","journal-title":"J Hepatol"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"M Kumar","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"C M Chu","year":"2004","journal-title":"Am J Med"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"M Cornberg","year":"2017","journal-title":"J Hepatol"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"W K Seto","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"606.e1","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"B Maasoumy","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.04.045","article-title":"Assay for hepatitis B core-related antigen identify patients with high viral load: systematic review and meta-analysis of individual participant data","author":"K Yoshida","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13054","article-title":"Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B","volume":"26","author":"E Loggi","year":"2019","journal-title":"J Viral Hepat"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"C J Chen","year":"2006","journal-title":"JAMA"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"G V Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"T C Tseng","year":"2012","journal-title":"Gastroenterology"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3350\/cmh.2020.0032","article-title":"Novel biomarkers for the management of chronic hepatitis B","volume":"26","author":"T Inoue","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis","volume":"58","author":"T Kumada","year":"2013","journal-title":"J Hepatol"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","article-title":"HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics","volume":"65","author":"T Tada","year":"2016","journal-title":"J Hepatol"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/jvh.13191","article-title":"Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma","volume":"26","author":"W P To","year":"2019","journal-title":"J Viral Hepat"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","article-title":"High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load","volume":"157","author":"T C Tseng","year":"2019","journal-title":"Gastroenterology"},{"issue":"15","key":"ref30","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Y F Liaw","year":"2004","journal-title":"N Engl J Med"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/jvh.12688","article-title":"Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy","volume":"24","author":"K S Cheung","year":"2017","journal-title":"J Viral Hepat"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/apt.15108","article-title":"Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues","volume":"49","author":"T Hosaka","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1478-3231.2010.02344.x","article-title":"HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy","volume":"30","author":"T Hosaka","year":"2010","journal-title":"Liver Int"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cca.2018.07.027","article-title":"Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients","volume":"486","author":"S Chen","year":"2018","journal-title":"Clin Chim Acta"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s12072-011-9265-z","article-title":"Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis","volume":"5","author":"T Yasunaka","year":"2011","journal-title":"Hepatol Int"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/apt.15429","article-title":"The role of hepatitis B core-related antigen in predicting hepatitis B virus recurrence after liver transplantation","volume":"50","author":"J Yu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cmi.2017.03.003","article-title":"Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype","volume":"23","author":"M Riveiro-Barciela","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/liv.13046","article-title":"Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"36","author":"N Chuaypen","year":"2016","journal-title":"Liver Int"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/jvh.13117","article-title":"Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B","volume":"26","author":"M JH van Campenhout","year":"2019","journal-title":"J Viral Hepat"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"306.e7","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy","volume":"24","author":"N Chuaypen","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"C L Lai","year":"2017","journal-title":"J Hepatol"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350801300106","article-title":"Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication","volume":"13","author":"M Lutgehetmann","year":"2008","journal-title":"Antivir Ther"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","author":"D K Wong","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1440-1746.2005.04087.x","article-title":"Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection","volume":"20","author":"A Rokuhara","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"issue":"08","key":"ref45","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"B Wang","year":"2018","journal-title":"J Viral Hepat"},{"issue":"07","key":"ref46","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/jvh.13097","article-title":"Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues","volume":"26","author":"M J Sonneveld","year":"2019","journal-title":"J Viral Hepat"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.livres.2017.06.002","article-title":"Stopping nucleos (t) ide analog treatment in chronic hepatitis B\u2014Who and when?","volume":"1","author":"S GR Kho-Herman","year":"2017","journal-title":"Liver Research"},{"issue":"S 01","key":"ref48","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/liv.13654","article-title":"Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B","volume":"38","author":"F van B\u00f6mmel","year":"2018","journal-title":"Liver Int"},{"issue":"08","key":"ref49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1872-034X.2007.00094.x","article-title":"Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy","volume":"37","author":"A Matsumoto","year":"2007","journal-title":"Hepatol Res"},{"issue":"08","key":"ref50","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/hepr.13504","article-title":"Japan Society of Hepatology guidelines for the management of hepatitis B virus infection: 2019 update","volume":"50","author":"A Tanaka","year":"2020","journal-title":"Hepatol Res"},{"issue":"08","key":"ref51","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"K S Jung","year":"2016","journal-title":"J Gastroenterol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100\u2009IU\/mL","author":"T N Tseng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients","volume":"222","author":"R Fan","year":"2020","journal-title":"J Infect Dis"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Y C Hsu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jvh.13211","article-title":"Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B","volume":"27","author":"M Papatheodoridi","year":"2020","journal-title":"J Viral Hepat"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/ajg.2016.436","article-title":"Association of hepatitis B core-related antigen with hepatitis b virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy","volume":"111","author":"W K Seto","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"A S Lok","year":"2017","journal-title":"Hepatology"},{"issue":"37","key":"ref59","doi-asserted-by":"crossref","first-page":"8314","DOI":"10.3748\/wjg.v22.i37.8314","article-title":"Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients","volume":"22","author":"H W Lee","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.13277","article-title":"Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma","volume":"49","author":"Y Suzuki","year":"2019","journal-title":"Hepatol Res"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1723088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T15:10:59Z","timestamp":1672067459000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1723088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":58,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,6,9]]},"published-print":{"date-parts":[[2021,5]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1723088","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}